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a B s t r a C t
the continuous replication of HiV-1 in the central 
nervous system, in particular the brain, and its potential 
long-term deleterious effect is the focus of this review. 
Cognitive deficits are observed in a significant percentage 
of HiV-1-infected patients. that may occur despite 
successful peripheral suppression of the HiV-1 replication. 
Compartmentalisation of HiV-1 in the brain, genetic 
mutation of HiV-1, age, HCV coinfection and poor 
intracerebral penetration, as well as possibly a direct toxic 
effect of antiretroviral drugs, are factors that may account 
for potential creeping damage of the brain after many 
years of treatment. Patients with neurological symptoms 
or cognitive deficits may require another approach to the 
treatment of their HiV infection.
K e y W o r d s
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i n t r o d U C t i o n
The central nervous system (CNS) is a major target of 
HIV-1 infection and HIV-1-related diseases.1,2 Chronic 
HIV-1 infection of the CNS begins during primary 
infection and continues in nearly all untreated seropositive 
individuals. Late during the course of systemic infection, 
asymptomatic and seemingly benign CNS disease can 
progress to more severe disease. The clinical presentation 
is heterogeneous and can include a syndrome of 
cognitive, motor, and behavioural dysfunction formerly 
known as AIDS dementia complex (ADC), now called 
HIV-associated dementia (HAD). Less serious stages are 
nowadays included in the collective term, HIV-associated 
neurocognitive disorders (HAND).3 In the late stages 
of immune suppression, the CNS is also vulnerable to 
opportunistic infections. This review will focus on the 
effects of HIV-1 infection on the CNS as well as the 
effects of combination antiretroviral therapy (ART) and its 
limitations with respect to the CNS. Consideration will be 
given to whether chronic infection in treated individuals 
has long-term neurological sequelae and, if so, whether 
they can be treated or even prevented. 
o V e r a l l  i m P a C t  o f  a r t  o n  a i d s - 
r e l a t e d  n e U r o l o G i C a l  d i s e a s e s 
Combination ART has substantially inf luenced 
HIV-induced CNS disease. The incidence of all 
AIDS-related CNS diseases is now markedly reduced, at 
least in developed countries. This was well documented 
in the EuroSIDA cohort study, which showed a tenfold 
decrease in CNS diseases that paralleled a decrease in 
systemic AIDS-related complications after combination 
ART was introduced.4 HAD was the most common severe 
CNS disease before the introduction of ART, and showed 
the greatest reduction in incidence between 1994 and 
2002.4 
Zidovudine was the first antiretroviral drug with 
therapeutic benefit on the course of HAD. But since an 
early AIDS Clinical Trials Group (ACTG) study (protocol 
005) showed this effect,5 few controlled treatment trials 
with other antiretroviral drugs have been performed. 
Although ART can clearly arrest HAD and reverse its 
neurological disability, the general magnitude of this 
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effect is variable and not precisely defined. Low CD4 
counts were an important risk factor for HAD in the 
era before combination ART, and continue to be so in 
the modern treatment era, also for the development of 
HAND.6 Additional risk factors for new or progressive 
HAND in the modern treatment era include incomplete 
immune recovery, rapid immune recovery with immune 
recovery inflammatory syndrome (IRIS),7 hepatitis C 
virus (HCV) coinfection,8-10 and advancing age.11 The 
aggregate experience that ART primarily ameliorates 
HAND, however, appears to be compelling, and indicates 
that neurological dysfunction can be reversed.11-14
C H r o n i C  C n s  H i V - 1  i n f e C t i o n : 
V i r o l o G i C a l  a n d  B i o C H e m i C a l 
a s P e C t s  a n d  i t s  C l i n i C a l  i m P a C t
In the absence of treatment, HIV replication in cells of 
the nervous system is a nearly constant component of 
HIV-1 infection and has been characterised most clearly 
by studies analysing cerebrospinal fluid (CSF). During 
life, it is not possible to measure HIV replication in the 
brain. Therefore, HIV RNA levels in the CSF together with 
markers of inflammation and neuropsychological tests are 
considered to give guidance on the degree of brain damage 
during the course of HIV-1 infection.15-17
HIV-1 RNA can be detected in the CSF of nearly all those 
with infection, from the period of initial viraemia through 
the course of neurologically asymptomatic infection and 
in those developing HAND.15-18 A number of studies have 
shown that HIV-1 RNA in CSF is nearly ubiquitous but 
variable in its magnitude and in its relation to HIV-1 RNA 
level in blood.15-21 Generally, in untreated individuals, CSF 
HIV-1 RNA levels are approximately tenfold lower than 
plasma HIV-1 RNA levels, but the difference between 
viral concentrations in the two fluids varies considerably 
with levels in CSF exceeding those in blood in some 
individuals. An example of the relationship between 
HIV RNA levels in CSF and blood is shown in figure 1. In 
general, HIV RNA levels in CSF correlate with those in 
blood although this correlation weakens in those who have 
advanced HIV disease or who have HAND.18 In addition 
to quantitative differences between CSF and blood, viral 
populations that are found in the nervous system can 
also diverge qualitatively from those in blood. Genetic 
compartmentalisation of HIV-1 has been demonstrated 
by several studies.22-27 During acute infection, HIV-1 
populations in CSF and blood are probably monophyletic, 
but then, during chronic infection, the populations expand 
and diverge, with the greatest divergence in patients 
who have HAND. Functional compartmentalisation has 
also been shown with respect to drug resistance, use of 
entry receptors, and cell tropism. Differences in drug 
susceptibility between CSF and blood HIV-1 populations 
have also been reported.28-31 Although viral replication in 
CSF in the presence of sub-therapeutic drug concentrations 
might enhance the selection of resistance mutations, few 
studies have carefully compared drug concentrations in 
CSF with the development of drug resistance.32 Recent 
findings on the adaptations of HIV-1 to neural cells33-35 have 
advanced our understanding of HIV-1 neuroadaptation 
and neurovirulence but additional work is needed to 
understand, for instance, the clinical implications of these 
and other findings. 
CSF analysis also indicates that HIV-1 infection is 
associated with chronic immune activation in the nervous 
system (neuroinflammation, as indicated by frequent, 
although usually mild, CSF pleocytosis and elevated 
levels of several soluble immunological markers19,36-38 
e.g. neopterin, b-2-microglobulin, quinolinic acid, and 
CCL2/MCP-1. The persistence of HIV-1 and the associated 
neuroinflammation raise the important question of 
whether chronic asymptomatic infection is accompanied 
by ongoing, low-grade brain injury despite the lack of overt 
symptoms and signs. If this chronic inflammatory37 state 
leads to brain injury, will survivors develop neurological 
impairment years later despite otherwise effective therapy? 
Several studies have reported neurocognitive impairment 
in HIV-infected patients, typically with a detrimental 
impact on activities of daily living (ADLs).1,4-43 Indeed, 
diminished group performance has led to the inclusion of 
the designation ‘HIV-associated asymptomatic neurological 
impairment’ (ANI) as a diagnosis subsumed in the 
HAND classification approach.3 The other diagnoses that 
comprise HAND are ‘mild neurocognitive disorder’, a 
milder symptomatic syndrome that clearly impacts ADLs, 
and ‘HIV-associated dementia’, a more severe, symptomatic 
figure 1. Plasma and CSF HIV RNA concentrations 
in 31 HIV-1 seropositive patients
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Plasma and Csf samples were taken at the same day with a maximal 
time span of one hour.
source: radboud University medical Center, department of General 
internal medicine, nijmegen, the netherlands.
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syndrome that markedly impacts ADLs. Neurocognitive 
impairment may persist despite successful treatment with 
antiretroviral therapy.42,43 Therefore combination ART for 
HIV-1 infection may incompletely treat the CNS. 
influence of art on Csf HiV rna
In general, HIV-1 in CSF responds very well to ART;44-51 
as HIV-1 RNA levels in plasma become undetectable, 
so do those in CSF in nearly all individuals. However, 
the relative rates of viral decay in the two compartments 
may differ in some, with HIV-1 RNA concentrations 
falling more slowly in CSF than in plasma. Slower decay 
has been noted in subjects with HAD and lower blood 
CD4 cell counts but without CSF pleocytosis.50-53 These 
observations can be interpreted as being consistent with a 
simple model of compartmentalised CSF HIV-1 infection, 
with the lag in viral response in CSF due to slow cell 
turnover and consequent prolonged virion production by 
brain macrophages, reduced trafficking of shorter-lived 
lymphocytes into the CSF from blood, and lower drug 
concentrations in the CNS. Drug penetration in the CNS 
largely depends on the physicochemical properties e.g. 
protein binding, molecule size, lipophilicity, or use of 
membrane transporters in the blood brain barrier such as 
P-glycoprotein. In addition drug penetration into the CNS 
also can be modified.54-56 Considerable differences exist 
between antiretroviral drugs with respect to penetration 
into the CNS. Letendre et al.56 have proposed a simple 
scheme for grouping drugs by CSF penetration ability 
based on drug properties and clinical studies, rating them 
as 0 (lower penetration), 0.5 (intermediate penetration), or 
1 (higher penetration). No drug concentrations in CSF have 
yet been published for newer antiretroviral drugs such as 
darunavir, etravirine, raltegravir, and maraviroc. 
Although potentially useful as a guide for selecting 
treatment, several observations suggest that the model 
may not fully account for treatment effects in all settings. 
For example, it may not explain the overall effectiveness 
of a wide variety of drug regimens in the suppression of 
CSF HIV-1 RNA levels or why cases of high CSF virus 
levels in the presence of suppressed plasma virus levels 
are rare. The very rapid decay of HIV-1 in CSF is equivalent 
to that of plasma virus in some subjects, which may 
reflect increased permeability of the blood-brain barrier or 
high levels of pretreatment lymphocyte trafficking. Such 
inter-individual differences may reflect differences in 
genetic traits, such as expression of chemokine receptors 
and adhesion molecules, or in comorbidities, such as 
recreational drug use and HCV coinfection. Also it should 
be stressed that potency of the complete (usually three 
drug) regimen and to what extent concentrations exceed 
the IC90 are more relevant than single drug concentrations 
in the CSF. This and the issues mentioned above are areas 
for ongoing and future research.
C n s  s i d e  e f f e C t s  o f  H a a r t 
To date, the most widely recognised antiretroviral 
with CNS side effects is the non-nucleoside reverse 
transcriptase inhibitor efavirenz.57 Vivid and dysphoric 
dreams, in particular during the first weeks of treatment, 
are commonly reported symptoms. Less than 10% 
discontinue treatment because of these symptoms. 
Prospective studies have not found a clear deleterious 
effect of efavirenz on longer term neuropsychological 
performance or on depressive scores,58,59 although the 
findings are not entirely consistent.60 The mechanism 
of these symptoms is not well understood, although 
they seem to be linked with higher levels of drug 
exposure.61,62 So far, no conclusive data show that other 
antiretroviral drugs have a direct toxic effect on the brain. 
However, some animal and human data on a potential 
deleterious effect of NRTI on brain mitochondria and 
cellular metabolism do exist.63 In addition there is some 
concern that drug-induced injury of mitochondria or 
changes in lipid metabolism, for example, may injure the 
brain, particularly in more vulnerable hosts (e.g., older 
individuals). 
a n t i r e t r o V i r a l  t H e r a P y  a n d 
n e U r o C o G n i t i V e  P e r f o r m a n C e
Would initiation of ART earlier in the course of HIV 
disease further reduce the risk of development of 
HAND? Hitherto, should treatment with neuroeffective 
antiretroviral drugs be recommended in all individuals at 
the time of treatment initiation?64 These questions cannot 
yet be confidently answered. Many issues should be taken 
into account in the treatment of HIV disease: in the first 
table 1. Categorisation of antiretroviral drugs by 
estimated neuroeffectiveness (CNS penetration-
effectiveness rank)
 Better intermediate Worse
NRTIs Abacavir Emtricitabine Didanosine
Zidovudine Lamivudine Tenofovir
  Stavudine Zalcitabine
NNRTIs Delavirdine Efavirenz
 Nevirapine   
PIs Amprenavir-r Amprenavir Nelfinavir
Indinavir-r Atazanavir Ritonavir
Lopinavir-r Atazanavir-r Saquinavir
Indinavir Saquinavir-r
   Tipranavir-r
Fusion
inhibitors
  Enfuvirtide
-r = drugs boosted by ritonavir. source: dr s. letendre.
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place potency, then toxicity, and also dosing simplicity. 
The literature on the effects of ART on neurocognitive 
performance is not entirely consistent. Case reports show 
improvement of symptoms of dementia that paralleled 
improvement of HIV RNA levels and the inflammatory 
markers in the CSF.67,68 Some research studies identified 
that more neuroeffective regimens were associated 
with greater improvement65,66 but others did not.69,70 
Important methodological differences between these 
studies exist including the approach to testing, the method 
of estimating neuroeffectiveness, the types of regimens 
used, and the demographic and disease characteristics 
of the study population. Importantly, improvement in 
neurocognitive performance is a secondary effect of 
control of HIV replication, which is the primary effect 
of ART. Control of HIV in the CNS is a necessary but 
not necessarily sufficient condition for neurocognitive 
protection or improvement. For all these reasons, 
caution must be exercised in interpretation of these 
research findings. Additional clinical trials to address the 
question whether ART regimens should be optimised for 
neuroeffectiveness are not easily performed but at least 
one is underway.71 Another important question for future 
clinical trials to address is the use of adjuvant therapies to 
improve intracerebral penetration.72-75
Given these uncertainties, how should treatment be 
tailored to the nervous system now? This question cannot 
easily be answered. The existing data so far indicate that 
in neurologically asymptomatic patients - that is, in most 
of those who initiate therapy - the CNS likely warrants 
no special consideration. However, in patients who have 
HAND, a different approach could be advocated. In these 
patients treatment could be initiated with a regimen that 
penetrates well into the CSF and into the brain. The effect 
then could be monitored by measurement of HIV RNA and 
drug levels in CSF as well as repeated neuropsychological 
tests. 
C o n C l U s i o n s
Although a number of important treatment issues have not 
yet been addressed, the advent of ART has had a profound 
impact on severe CNS disease as a complication of HIV-1 
infection. This impact includes a marked reduction in 
the incidence of major CNS opportunistic infections and 
HAD, and effective treatment for patients presenting with 
new-onset HAND. With this success, attention has turned 
to other aspects of CNS HIV-1 infection and particularly to 
the question of the optimal management of milder, but still 
clinically relevant, HAND syndromes. CNS HIV-1 infection 
and the associated neuroinflammation may damage the 
brain during the long period before treatment is initiated 
and may even continue in the presence of effective 
systemic viral suppression. Now that the most conspicuous 
and severe neurological complications of HIV-1 infection 
can be avoided in most cases, the effects of therapy on the 
remaining clinical syndromes of brain injury must be 
carefully considered and explored.
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